Unlocking the opportunity of NAMPT inhibition
NEWS: Remedy to present data at 66th ASH Annual Meeting December 7-10, 2024. Visit our Media page for more information!
The next wave of NAMPT therapeutics
The technology and research program at Remedy Plan are both exciting and novel. They have a great opportunity to develop drugs that effectively block cancer recurrence and metastasis.
Frank McCormick
Founder of Onyx Pharmaceuticals, professor at the UCSF Helen Diller Cancer Center, Fellow of Royal Society, and member of the National Academies of Science
Remedy Plan drug candidates
We use a proprietary drug screening platform to discover and optimize new drugs that target core vulnerabilities in cancer cells. Our team’s NAMPT breakthroughs also led to exciting opportunities to treat autoimmune and metabolic diseases.
- Discovery
- Proof-of-Concept
- Lead Optimization
- IND-Enabling
- Phase I
- NAMPT - Oncology: RPT1G
- NAMPT - Autoimmune
- NAMPT - Obesity
- Target 2
I'm very impressed by the creative and novel approach being used by Remedy Plan to identify new drugs that render cancer cells harmless.
Dan Portnoy
Professor at UC Berkeley, member of the National Academies of Science, and an NIH Merit Award recipient
Remedy Plan is a team of scientists and biotech entrepreneurs dedicated to tackling the biggest health problem of our time.